首页> 中文期刊> 《右江民族医学院学报》 >贝那普利和氯沙坦联合治疗肾实质性高血压45例疗效与安全性观察

贝那普利和氯沙坦联合治疗肾实质性高血压45例疗效与安全性观察

         

摘要

Objective To observe the efficacy and safety of benazepril combined with losartan in treatment of renal parenchymal hypertension. Methods Eighty - nine patients with renal parenchymal hypertension cared at our hospital from January 2014 to March 2015 were divided into two groups by using a hidden random number method.The control group (44 cases)was treated with losartan.The study group received (45 cases) benazepril combined with losartan.Blood pressure,serum creatinine (SCr),blood urea nitrogen (BUN),uric acid and 24h urine protein (24Hup)were measured before treatment and 3 months after treatment.The ad-verse reactions were recorded. Results After treatment,DBP and SBP in the two groups were significantly lower than those before treatment.After treatment,BUN,24Hup and SCr in the study group were lower than those before treatment,comparison showed statistical difference (P <0.05).In the control group,there was no significant decrease in BUN after treatment (P >0.05),and 24Hup and SCr were lower than those before treatment (P <0.05).The reduction of SBP and DBP in the study group was significantly higher than those in the control group (P < 0.05 ),and the decrease of 24Hup was significantly higher than that in the control group (P <0.05).The adverse reaction rate was 6.67% in the study group and 4.55% in the control group, comparison yielded no statistical difference (χ2 =0.000,P =1.000). Conclusion Benazepril combined with losartan in the treatment of renal parenchymal hypertension has good effect on lowering blood pressure,can al-so reduce urine protein,and the safety is good.%目的:观察贝那普利和氯沙坦联合治疗肾实质性高血压的疗效与安全性。方法选择我院2014年1月~2015年3月肾实质性高血压患者89例,采用隐藏数字随机法分为两组,对照组44例给予氯沙坦治疗,研究组45例给予贝那普利和氯沙坦联合治疗,治疗前和治疗后3个月检测血压、血肌酐(SCr)、尿素氮(BUN)、24 h 尿蛋白(24Hup)等,记录用药期间不良反应。结果治疗后两组收缩压(SBP)、舒张压(DBP)较治疗前显著下降,研究组治疗后 SCr、BUN、24Hup较治疗前降低(P <0.05)。对照组治疗后 BUN 无明显降低(P >0.05),SCr、24Hup 较治疗前降低(P <0.05)。研究组治疗后 SBP、DBP 降低幅度大于对照组(P <0.05),24Hup 降低幅度大于对照组(P <0.05)。研究组不良反应发生率为6.67%,对照组不良反应发生率为4.55%,两组比较差异无统计学意义(χ2=0.000,P =1.000)。结论贝那普利和氯沙坦联合治疗肾实质性高血压降压效果好,还可降低尿蛋白,而且安全性好。

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号